Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trial-Reference-Cited by-同舟云学术

Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trial

Published:2023-08 Issue:8 Volume:41 Page:356.e19-356.e30
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Heinzelbecker Julia^ORCID,Spieler Natalie,Kuehn Michael,Fischer Claus,Volkmer Björn,von Rundstedt Friedrich,Albers Peter,Becht Eduard,Bannowsky Andreas,Weber H. Matthias,Hofmann Rainer,Müller Markus,Langbein Sigrun,Steiner Gabriel,Retz Margitta,Kamradt Jörn,Wagenpfeil Gudrun,Wellek Stefan,Lehmann Jan,Stoeckle Michael

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference31 articles.

1. Witjes JA, Bruins HM, Cathomas R, Compérat E, Cowan NC, Efstathiou JA, et al. EAU Guidelines on muscle-invasive and metastatic bladder cancer. EAU Guidel. Edn. presented at the EAU Annual Congress Milan 2021, Arnhem, The Netherlands: EAU Guidelines Office; n.d.

2. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer;Bochner;J Clin Oncol Off J Am Soc Clin Oncol,2006

3. Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis of individual participant data from randomised controlled trials;Eur Urol,2022

4. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data;Vale;Eur Urol,2005

5. Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy;Galsky;J Clin Oncol Off J Am Soc Clin Oncol,2011